{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:41Z","timestamp":1793298941349,"version":"4.5.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"\n Importance<\/jats:title>\n Overweight and obesity affect 60% to 78% of patients with psoriasis, affecting disease severity, treatment response, and clinical outcomes. However, no large, randomized, active-controlled clinical trial has evaluated a treatment strategy that addresses both diseases simultaneously.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To evaluate the efficacy and safety of ixekizumab with or without tirzepatide in participants with psoriasis and overweight or obesity.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This phase 3b, randomized, open-label, 52-week clinical trial was conducted at 72 sites in the US in adults with moderate to severe plaque psoriasis who have overweight with 1 or more weight-related comorbidities or obesity. The trial started on September 30, 2024, and completed the week 36 primary end point on January 8, 2026. Data were analyzed from January to February 2026.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Participants were randomized (1:1) to ixekizumab plus tirzepatide or ixekizumab as adjunct to diet and exercise in both treatment arms.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n At week 36, the primary end point was simultaneous achievement of Psoriasis Activity and Severity Index (PASI) 100 and 10% or greater weight reduction. Key secondary end points were PASI 100 and simultaneous PASI 75 and 5% or greater weight reduction, as well as 10% or greater weight reduction.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Among the 274 randomized participants (mean [SD] age, 45.6 [12.7] years; 123 [44.9%] women and 151 [55.1%] men; mean [SD] screening body mass index [calculated as weight in kilograms divided by height in meters squared], 39.2 [9.1]; mean [SD] duration of psoriasis, 14.6 [13.0] years; mean [SD] PASI, 19.7 [8.1]), 231 (84.3%) completed the treatment through week 36. Overall, 27.1% of participants simultaneously achieved PASI 100 and a 10% or greater weight reduction with ixekizumab plus tirzepatide vs 5.8% with ixekizumab (risk difference [RD], 21.2%; 95% CI, 12.8%-29.7%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). Also, 40.6% vs 29.0% of participants achieved PASI 100 (RD, 11.6%; 95% CI, 0.3%-22.9%;\n P<\/jats:italic>\n \u2009=\u2009.04), 79.9% vs 17.9% simultaneously achieved PASI 75 and a 5% or greater weight reduction (RD, 62.0%; 95% CI, 51.7%-72.2%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and 69.2% vs 9.1% achieved a 10% or greater weight reduction (RD, 60.0%; 95% CI, 50.4%-69.7%;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), respectively. Adverse events were generally consistent with established drug safety profiles, the most common being gastrointestinal tract events and injection site reactions. Gastrointestinal tract events occurred more frequently with ixekizumab plus tirzepatide vs ixekizumab.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n The trial results suggest that concomitant ixekizumab and tirzepatide produced clinically meaningful, statistically significant improvements in skin clearance and reductions in weight in participants with moderate to severe psoriasis, with no new safety concerns, while providing additional cardiometabolic benefits and a potential to elevate care.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT06588283<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2026.1753","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T16:30:20Z","timestamp":1778862620000},"page":"709","source":"Crossref","is-referenced-by-count":22,"title":["Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity"],"prefix":"10.1001","volume":"162","author":[{"given":"Mark","family":"Lebwohl","sequence":"first","affiliation":[{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"Blauvelt Consulting, LLC, Annapolis, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia E.","family":"Kartman","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cianna","family":"Leatherwood","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Gordon","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[{"name":"School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Aut\u00f2noma de Barcelona School of Medicine, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Department of Medicine, Division of Rheumatology, UT Southwestern Medical Center and O\u2019Donnell School of Public Health, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Siu","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Wang","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luna","family":"Sun","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Leung","sequence":"additional","affiliation":[{"name":"Syneos Health, Morrisville, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najwa","family":"Somani","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Rueda","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabela","family":"Cardoso","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Genovese","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company, Indianapolis, Indiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April W.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Division of Dermatology, University of California Los Angeles David Geffen School of Medicine, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Strober","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut"},{"name":"Central Connecticut Dermatology Research, Cromwell"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi260020r1","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/j.1529-8019.2010.01304.x","article-title":"Epidemiology of comorbidities in psoriasis.","volume":"23","author":"Naldi","year":"2010","journal-title":"Dermatol Ther"},{"issue":"6","key":"doi260020r2","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1159\/000455840","article-title":"Psoriasis and obesity.","volume":"232","author":"Jensen","year":"2016","journal-title":"Dermatology"},{"issue":"11","key":"doi260020r3","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.3390\/medicina59112006","article-title":"An observational study of 147 psoriasis patients: overweightness and obesity as a significant clinical factors correlated with psoriasis.","volume":"59","author":"Czarnecka","year":"2023","journal-title":"Medicina (Kaunas)"},{"issue":"6","key":"doi260020r4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103577","article-title":"Global prevalence of obesity in patients with psoriasis: an analysis in the past two decades.","volume":"23","author":"Wang","year":"2024","journal-title":"Autoimmun Rev"},{"issue":"12","key":"doi260020r6","doi-asserted-by":"publisher","DOI":"10.1038\/nutd.2012.26","article-title":"The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies.","volume":"2","author":"Armstrong","year":"2012","journal-title":"Nutr Diabetes"},{"issue":"1","key":"doi260020r7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","article-title":"Psoriasis and the metabolic syndrome.","volume":"36","author":"Gisondi","year":"2018","journal-title":"Clin Dermatol"},{"issue":"4","key":"doi260020r8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/bjd.18327","article-title":"Comparable efficacy and safety of brodalumab in obese and nonobese patients with psoriasis: analysis of two randomized controlled trials.","volume":"182","author":"Hsu","year":"2020","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi260020r9","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1016\/j.jaad.2021.06.012","article-title":"Risk of psoriasis according to body mass index: A retrospective cohort analysis.","volume":"86","author":"Norden","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"doi260020r10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.590749","article-title":"Adipokines, cardiovascular risk, and therapeutic management in obesity and psoriatic arthritis.","volume":"11","author":"Porta","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"doi260020r11","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40744-020-00215-6","article-title":"Obesity and psoriatic arthritis: a narrative review.","volume":"7","author":"Kumthekar","year":"2020","journal-title":"Rheumatol Ther"},{"issue":"8041","key":"doi260020r12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1038\/s41586-024-08131-3","article-title":"Rhythmic IL-17 production by ?d T cells maintains adipose de novo lipogenesis.","volume":"636","author":"Douglas","year":"2024","journal-title":"Nature"},{"issue":"7","key":"doi260020r13","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1001\/jamadermatol.2013.722","article-title":"Effect of weight loss on the severity of psoriasis: a randomized clinical study.","volume":"149","author":"Jensen","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi260020r14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/bjd.17741","article-title":"Does weight loss reduce the severity and incidence of psoriasis or psoriatic arthritis? a critically appraised topic.","volume":"181","author":"Mahil","year":"2019","journal-title":"Br J Dermatol"},{"issue":"10","key":"doi260020r15","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s40261-021-01080-z","article-title":"Impact of body mass index on the efficacy of biological therapies in patients with psoriasis: a real-world study.","volume":"41","author":"Pirro","year":"2021","journal-title":"Clin Drug Investig"},{"issue":"4","key":"doi260020r16","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.jaad.2024.12.016","article-title":"The association between obesity and efficacy of psoriasis therapies: an expert consensus panel.","volume":"92","author":"Burshtein","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"doi260020r17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3389\/fphar.2020.00117","article-title":"Pathogenesis of chronic plaque psoriasis and its intersection with cardio-metabolic comorbidities.","volume":"11","author":"Gisondi","year":"2020","journal-title":"Front Pharmacol"},{"issue":"4","key":"doi260020r18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","article-title":"Managing the patient with psoriasis and metabolic comorbidities.","volume":"25","author":"Bellinato","year":"2024","journal-title":"Am J Clin Dermatol"},{"issue":"14","key":"doi260020r19","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis.","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"doi260020r20","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials.","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"9993","key":"doi260020r21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"issue":"10148","key":"doi260020r22","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"issue":"10201","key":"doi260020r23","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"issue":"10273","key":"doi260020r24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"doi260020r25","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week.","volume":"77","author":"Garshick","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"doi260020r26","doi-asserted-by":"publisher","DOI":"10.1111\/obr.13112","article-title":"Cardiovascular outcome trials in obesity: a review.","volume":"22","author":"Wilding","year":"2021","journal-title":"Obes Rev"},{"issue":"4","key":"doi260020r27","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities.","volume":"80","author":"Elmets","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi260020r28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity.","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"doi260020r29","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity.","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"doi260020r30","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107845","article-title":"The role of incretins and incretin-based drugs in autoimmune diseases.","volume":"98","author":"Radbakhsh","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"doi260020r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists.","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"1","key":"doi260020r32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/bjd\/ljaf346","article-title":"Glucagon-like peptide-1 receptor agonists and reduced mortality, cardiovascular and psychiatric risks in patients with psoriasis: a large-scale cohort study.","volume":"194","author":"Olbrich","year":"2026","journal-title":"Br J Dermatol"},{"key":"doi260020r33","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70247","article-title":"Impact of weight-loss interventions on psoriasis severity: a systematic review and meta-analysis.","author":"Morrow","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi260020r34","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis.","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"doi260020r35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 Phase-3 randomized controlled trials.","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"doi260020r36","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/jdv.15921","article-title":"Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study.","volume":"34","author":"Lebwohl","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"doi260020r37","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1111\/bjd.15666","article-title":"Comparison of ixekizumab with ustekinumab in moderate-to-severe psoriasis: 24-week results from IXORA-S, a phase III study.","volume":"177","author":"Reich","year":"2017","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi260020r38","doi-asserted-by":"publisher","first-page":"1348","DOI":"10.1111\/bjd.18851","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.","volume":"182","author":"Blauvelt","year":"2020","journal-title":"Br J Dermatol"},{"issue":"6","key":"doi260020r39","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial.","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi260020r40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1136\/annrheumdis-2019-215386","article-title":"A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na\u00efve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.","volume":"79","author":"Mease","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"10402","key":"doi260020r41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"key":"doi260020r42","doi-asserted-by":"publisher","DOI":"10.1002\/art.70134","article-title":"Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial.","author":"Merola","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"doi260020r45","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1002\/sim.3495","article-title":"A graphical approach to sequentially rejective multiple test procedures.","volume":"28","author":"Bretz","year":"2009","journal-title":"Stat Med"},{"issue":"6","key":"doi260020r46","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/bimj.201000239","article-title":"Graphical approaches for multiple comparison procedures using weighted Bonferroni, Simes, or parametric tests.","volume":"53","author":"Bretz","year":"2011","journal-title":"Biom J"},{"issue":"10","key":"doi260020r47","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1007\/s13555-024-01261-6","article-title":"Complete skin clearance is associated with the greatest benefits to health-related quality of life and perceived symptoms for patients with psoriasis.","volume":"14","author":"Augustin","year":"2024","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"doi260020r48","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1177\/24755303231160683","article-title":"Psoriasis involving special areas is associated with worse quality of life, depression, and limitations in the ability to participate in social roles and activities.","volume":"8","author":"Blauvelt","year":"2023","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"1","key":"doi260020r49","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2018.02.074","article-title":"Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: results from UNCOVER-1, UNCOVER-2, and UNCOVER-3.","volume":"79","author":"Egeberg","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"doi260020r5","author":"Armstrong","year":"2026"},{"key":"doi260020r43","unstructured":"International Council for Harmonisation. Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. Accessed June 05, 2023. https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf"},{"key":"doi260020r44","unstructured":"US Food and Drug Administration. Adjusting for covariates in randomized clinical trials for drugs and biological products. Accessed February 20, 2026. https:\/\/www.fda.gov\/media\/148910\/download"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2849327\/jamadermatology_lebwohl_2026_oi_260020_1783528893.7764.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:00:43Z","timestamp":1784127643000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2849327"}},"subtitle":["A Phase 3b Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":49,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2026.1753","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}